Published in Cancer Weekly, October 24th, 2006
"Oligonucleotides containing CpG motifs and IMO containing a synthetic immunostimulatory dinucleotide and a novel DNA structure have been suggested to have potential for the treatment of various human diseases. In the present study, a newly designed IMO was evaluated in several models of human (MCF-7 and BT474 xenograft) and murine (4T1 syngeneic) breast cancer," wrote H. Wang and colleagues, University of Alabama.
"Pharmacokinetics studies of the IMO administered by s.c., i.v., p.o., or i.p. routes were also accomplished....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.